Financing of Myovant Sciences

Myovant Sciences (NYSE: MYOV), a biopharmaceutical company focused on the innovative treatment of endocrine diseases, has secured flexible financing commitments of up to USD 140 million from NovaQuest Capital Management and Hercules Capital, Inc. The proceeds from both financings will be used to fund the ongoing Phase 3 development of Myovant's lead compound "relugolix".

VISCHER advised Myovant Sciences as Swiss counsel. The VISCHER team includes Dr. Adrian Dörig (Partner, Corporate), Christoph Niederer (Partner, Tax), Sebastian Flückiger (Associate, Corporate), Ruben Masar (Associate, Corporate) and Seraina Tsering (Associate, Corporate ).

Adrian Dörig

Attorney at Law

• Partner

• +41 58 211 34 89
• [email protected]

Christoph Niederer

Attorney at Law, Swiss Certified Tax Expert

• Partner

• +41 58 211 34 37
• [email protected]

Ruben Masar

Attorney at Law, Honorary Consul of the Slovak Republic

• Managing Associate

• +41 58 211 33 38
• [email protected]